“…We excluded 19 CPGs (eFigure in Supplement 1). [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63] Of the 32 included CPGs, 3 (9.4%) 15,38,40 reported on pharmacologic treatments for critically ill patients specifically, and the remainder reported on treatments for hospitalized patients with COVID-19. Fifteen CPGs (46.9%) were international 15,16,20,21,23,24,27,[31][32][33][34]36,38,43,44 and 17 (53.1%) were national.…”